Remdesivir
Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases.